← Leaderboards
Ramesh Vemulapalli
Purdue University West Lafayette
$2,162,602
Attributed
$2,162,602
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $313.6K · FY2008–22$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,162,602 · 4
By mechanism
R01$1,206,275 · 1
R21$941,327 · 2
R13$15,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BasePathogenCategoriesInfectionLifeMouse ModelSafetyDeveloping CountriesMammalsBacteriaConjunctivaMeat ProductsChronicMalaiseAnimal TissueBrucella Abortus BacteriumInfertilityBreathingAnimalsBrucella Melitensis BacteriumBody SystemBrucellosisAffectBrucella
Grant awards (9)
Occidiofungin as a new lead against the enteric AIDS-OI cryptosporidium$185,637
R21 · FY2022 · AI · contact PI
Occidiofungin as a new lead against the enteric AIDS-OI cryptosporidium$223,690
R21 · FY2021 · AI · contact PI
Non-replicative Vaccine for Human Brucellosis$293,922
R01 · FY2011 · AI · contact PI
Non-replicative Vaccine for Human Brucellosis$297,194
R01 · FY2010 · AI · contact PI
Brucellosis Research Conference 2009$15,000
R13 · FY2010 · AI · contact PI
Non-replicative Vaccine for Human Brucellosis$313,608
R01 · FY2009 · AI · contact PI
Non-replicative Vaccine for Human Brucellosis$301,551
R01 · FY2008 · AI · contact PI
B.abortus-based vaccine against viral hemorrhagic fevers$266,000
R21 · FY2004 · AI
B.abortus-based vaccine against viral hemorrhagic fevers$266,000
R21 · FY2003 · AI